Ramaiah Medical College and Hospitals, Bengaluru, Karnataka 560054, India.
Cornwall Partnership NHS Foundation Trust, Threemilestone Industrial Estate, Truro TR4 9LD, UK; Exeter Medical School, Knowledge Spa, Royal Cornwall Hospital, Truro, Cornwall TR1 3HD, UK.
Epilepsy Behav. 2018 Mar;80:365-369. doi: 10.1016/j.yebeh.2018.01.020. Epub 2018 Feb 5.
Psychiatric and behavioral side effects (PBSEs) are a major cause of antiepileptic drug (AED) withdrawal. Levetiracetam (LEV) is a recognized first-line AED with good seizure outcomes but recognized with PBSEs. Eslicarbazepine (ESL) is considered to function similarly to an active metabolite of the commonly used carbamazepine (CBZ). Carbamazepine is used as psychotropic medication to assist in various psychiatric illnesses such as mood disorders, aggression, and anxiety.
The aim was to evaluate the psychiatric profile of ESL in people who had LEV withdrawn due to PBSEs in routine clinical practice to see if ESL can be used as a possible alternative to LEV.
A retrospective observational review was conducted in two UK epilepsy centers looking at all cases exposed to ESL since its licensing in 2010. The ESL group was all patients with treatment-resistant epilepsy who developed intolerable PBSEs to LEV, subsequently trialed on ESL. The ESL group was matched to a group who tolerated LEV without intolerable PBSEs. Psychiatric disorders were identified from case notes. The Hamilton Depression Scale (HAM-D) was used to outcome change in mood. Clinical diagnoses of a mental disorder were compared between groups using the Fisher's exact test. Group differences in HAM-D scores were assessed using the independent samples t-test (alpha=0.05).
The total number of people with active epilepsy in the two centers was 2142 of whom 46 had been exposed to ESL. Twenty-six had previous exposure to LEV and had intolerable PBSEs who were matched to a person tolerating LEV. There was no statistical differences in the two groups for mental disorders including mood as measured by HAM-D (Chi-square test: p=0.28).
The ESL was well tolerated and did not produce significant PBSEs in those who had PBSEs with LEV leading to withdrawal of the drug. Though numbers were small, the findings suggest that ESL could be a treatment option in those who develop PBSEs with LEV and possibly other AEDs.
精神和行为副作用(PBSEs)是抗癫痫药物(AED)停药的主要原因。左乙拉西坦(LEV)是一种公认的一线 AED,具有良好的疗效,但也存在 PBSEs。依佐加滨(ESL)被认为与常用的卡马西平(CBZ)的一种活性代谢物的作用相似。卡马西平被用作精神药物,以协助治疗各种精神疾病,如情绪障碍、攻击行为和焦虑症。
本研究旨在评估在常规临床实践中因 PBSE 而停用 LEV 的患者中 ESL 的精神状态,以确定 ESL 是否可以作为 LEV 的替代药物。
在英国的两家癫痫中心进行了一项回顾性观察性研究,对自 2010 年 ESL 获得许可以来所有接受过 ESL 治疗的病例进行了研究。ESL 组均为患有耐药性癫痫且对 LEV 产生无法耐受的 PBSE 的患者,随后进行了 ESL 试验。ESL 组与一组对 LEV 耐受且无不可耐受的 PBSE 的患者进行了匹配。从病历中确定了精神疾病。使用汉密尔顿抑郁量表(HAM-D)评估情绪变化的结果。使用 Fisher 精确检验比较两组之间精神障碍的临床诊断。使用独立样本 t 检验(alpha=0.05)评估 HAM-D 评分的组间差异。
在这两个中心,活跃的癫痫患者总数为 2142 人,其中 46 人接受了 ESL 治疗。26 人以前曾接触过 LEV,并因不可耐受的 PBSE 而停药,与一名对 LEV 耐受的患者进行了匹配。两组在精神障碍方面(包括 HAM-D 测量的情绪)没有统计学差异(卡方检验:p=0.28)。
ESL 耐受性良好,在因 LEV 引起 PBSE 而停药的患者中未产生明显的 PBSEs。尽管数量较少,但这些发现表明,ESL 可能是那些因 LEV 和其他可能的 AED 引起 PBSEs 而出现 PBSEs 的患者的治疗选择。